AstraZeneca to invest $50 bn in the US amid Trump tariffs

AstraZeneca, a British pharmaceutical company, plans to invest $50 billion in the United States. This decision comes amid upcoming tariff increases from Washington. A significant portion of the investment will be used to construct a large manufacturing facility in Virginia. The company anticipates that 50 percent of its revenue will originate from the United States by the year 2030.